The case for medical marijuana in epilepsy

  title={The case for medical marijuana in epilepsy},
  author={Edward H. Maa and Paige Figi},
Charlotte, a little girl with SCN1A‐confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado‐based medical marijuana group (Realm of Caring), Charlotte's mother started adjunctive therapy with a high concentration cannabidiol/Δ9‐tetrahydrocannabinol (CBD:THC) strain of cannabis, now known as Charlotte's Web. This extract, slowly titrated over weeks and given in conjunction with her existing antiepileptic… Expand

Paper Mentions

Interventional Clinical Trial
EudraCT: 2018-003887-29 Objective:To evaluate the safety and efficacy of: MGCND00EP1 from MGC PHARMACEUTICALS d.o.o. Study Design: Randomized, double blind, placebo… Expand
ConditionsAdolescent Epilepsy, Children and Adolescents With Resistant Epilepsies, Children Epilepsy, (+1 more)
InterventionDiagnostic Test, Drug
Marijuana derivatives in epilepsy treatment in childhood – Current knowledge
Current knowledge on ‘medical’ marijuana in epilepsy is presented to present current knowledge on anticonvulsant properties of CBD in humans. Expand
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin
The patient affected by symptomatic partial epilepsy who used cannabis as self‐medication after the failure of countless pharmacological/surgical treatments supports the hypothesis that cannabis could actually represent an effective, well‐tolerated antiepileptic drug and suggests that CBDV may greatly contribute to cannabis anticonvulsant effect through its possible GABAergic action. Expand
Cannabinoids for paediatric epilepsy: Weeding out the issues
There has been increasing media interest and public discussion regarding a potential utility for cannabis in paediatric epilepsy, and there is strong theoretical and experimental evidence from animal studies to suggest that cannabinoids may be effective anticonvulsants. Expand
The Knowledge Gaps for Medical Marijuana in Pediatric Conditions.
Patients, families, and physicians are confronted with a scarcity of evidence on the safety, efficacy, and tolerability of cannabinoids in the face of abundantEvidence on the long-term harms of marijuana use. Expand
Cannabinoids in treatment-resistant epilepsy: A review
Open-label studies with 100mg/ml CBD have provided additional evidence of its efficacy along with an adequate safety profile in children and young adults with a spectrum of TREs and Phase 3 RCTs with Epidiolex support efficacy and adequate safety profiles for children with DS and LGS. Expand
Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
It is necessary to investigate CBD safety, pharmacokinetics and interaction with other AEDs alongside performing double-blinded placebo-controlled trials to obtain conclusive data on its efficacy and safety in the most frequent epilepsies in children, not just in the epileptic encephalopathy. Expand
Marijuana Compounds: A Non-Conventional Therapeutic Approach to Epilepsy in Children
Principal concerns regarding the use of medical marijuana in children include lack of standardization and regulation, imprecise dosing, possible adverse side effects and medication interactions. Expand
Development of cannabidiol as a treatment for severe childhood epilepsies
The introduction of CBD as the medicine Epidiolex in the United States and as Epidyolex in the European Union as the first cannabis‐derived therapeutic for the treatment of seizures was underpinned by preclinical research performed at the University of Reading, which was awarded the British Pharmacological Society Sir James Black Award for Contributions to Drug Discovery 2019. Expand
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
  • E. Perucca
  • Medicine
  • Journal of epilepsy research
  • 2017
There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes, for the first time, according to currently available information. Expand
Cannabidiol in the Treatment of Epilepsy
The aim of this article is to thoroughly review available research data and practical recommendations to provide the treating physician with the necessary information for counseling patients with epilepsy. Expand


Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Four of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition, while CBD was ineffective in 1 patient. Expand
Antiepileptic and Prophylactic Effects of Tetrahydrocannabinols in Amygdaloid Kindled Cats *
It is suggested that chronic administration of δ9‐THC during kindling might block the process of seizure development, which was supported by the observation that three of four cats failed to kindle when treated with the drug. Expand
Use of complementary and alternative medicine in an urban county hospital epilepsy clinic
This study was notable for the high rate of CAM utilization in a largely indigent population, with high rates of perceived efficacy among several CAM modalities. Expand
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
Particular focus will be placed on phytocannabinoid‐terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin‐resistant Staphylococcus aureus). Expand
Chemical constituents of marijuana: the complex mixture of natural cannabinoids.
The chemical constituents of the plant are discussed with particular emphasis on the cannabinoids as the class of compounds responsible for the drug's psychological properties. Expand
On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures.
  • B. Lutz
  • Biology, Medicine
  • Biochemical pharmacology
  • 2004
The concept that the endogenous cannabinoid system is activated on demand suggests that a promising strategy to alleviate seizure frequency is the enhancement of endocannabinoid levels by inhibiting the cellular uptake and the degradation of these endogenous compounds. Expand
Effects of Tetrahydrocannabinols on Kindled Amygdaloid Seizures and Photogenic Seizures in Senegalese Baboons, Papio papio
Intraperitoneal injections of delta 8‐tetrahy‐drocannabinol (THC) and delta 9‐THC failed to affect myoclonic response to photic stimulation in Senegalese baboons (Papio papio). However. both isomersExpand
Agonistic Properties of Cannabidiol at 5-HT1a Receptors
These studies demonstrate that CBD is a modest affinity agonist at the human 5-HT1a receptor, and indicate that cannabidiol may have interesting and useful potential beyond the realm of cannabinoid receptors. Expand
Anticonvulsant nature of marihuana smoking.
Marihuana smoking, in conjunction with therapeutic doses of phenobarbital and diphenylhydantoin, was apparently necessary for controlling seizures in one 24-year-old epileptic patient.
The orphan receptor GPR55 is a novel cannabinoid receptor
The endocannabinoid system functions through two well characterized receptor systems, the CB1 and CB2 receptors. Work by a number of groups in recent years has provided evidence that the system isExpand